Delivery Order SPE2DB20D1100-SPE2DB25FD5J1
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,269.61 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 mL pen (semaglutide injection), a GLP-1 receptor agonist medication used for weight management. The contract was awarded on September 2, 2025, with an ultimate completion date of September 3, 2025, and represents a firm fixed price, non-set-aside competitive procurement. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,205.84 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen (semaglutide injection), a GLP-1 receptor agonist commonly prescribed for weight management. This firm fixed-price delivery order, awarded on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major...
- The Defense Logistics Agency awarded a delivery order valued at $9,140.61 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen (semaglutide), a GLP-1 receptor agonist medication used for weight management. This firm fixed-price delivery order, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a competitive award with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,607.35 to AmerisourceBergen Drug Corp for ZEPBOUND 5 mg/0.5 mL pen (semaglutide injection), a GLP-1 receptor agonist medication used in diabetes and weight management treatment. This firm fixed-price, competitively awarded delivery order was issued on June 10, 2025, with an ultimate completion date of June 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $3,875.17 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen (semaglutide injection), a GLP-1 receptor agonist used for weight management. This firm fixed price delivery order was competitively awarded without set-aside restrictions and is scheduled for completion by August 4, 2025. The contract was awarded on August 1, 2025, with performance taking place at AmerisourceBergen's Conshohocken, Pennsylvania location, the...
- The Defense Logistics Agency awarded a delivery order valued at $3,050.32 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injectors on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price delivery order was placed under a non-set-aside procurement and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award reflects the agency's need for this...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 mL pen (semaglutide injection), a GLP-1 receptor agonist used in diabetes and weight management treatment. This firm fixed-price delivery order, issued on August 13, 2025, with an ultimate completion date of August 14, 2025, represents a competitively awarded contract with no set-aside designation. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $2,819.81 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen (semaglutide injection) on August 25, 2025, with completion scheduled for August 26, 2025. This is a firm fixed price, non-set-aside contract with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $10,380.95 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections on August 12, 2025, with an ultimate completion date of August 13, 2025. This firm fixed-price delivery order, issued without a set-aside designation, represents a competitive award to the pharmaceutical distributor and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract involves...
- The Defense Logistics Agency awarded a delivery order valued at $10,186.58 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections. This firm fixed price, non-set-aside delivery order was issued on August 27, 2025, with an ultimate completion date of August 28, 2025. The products will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD5J1Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,906.45 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen (semaglutide injection), a GLP-1 receptor agonist used for weight management. This competitively awarded, firm fixed-price delivery order was issued on July 18, 2025, with an ultimate completion date of July 21, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This delivery order represents a discrete purchase under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC SPE2DX) with DLA Troop Support Medical, a $999,999,999.00 comprehensive global pharmaceutical support vehicle valued through December 2026. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp supplies a broad spectrum of medications and medical commodities to support military healthcare systems worldwide, including specialty medications, brand-name and generic drugs, vaccines, and related medical supplies. The company's substantial federal contract portfolio demonstrates its established capability to fulfill federal medical procurement requirements across multiple therapeutic domains and customer bases, including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 7/18/25 |